300254SZSE
🚨 Material Event

2026 Restricted Stock Incentive Plan Implementation Assessment Management Measures

Qianyuan Pharmaceutical Co., Ltd.··4 pages

✨ AI Summary

Shanxi Qianyuan Pharmaceutical Group Co., Ltd. has established these measures to incentivize directors, senior management, and core personnel. The plan links restricted stock vesting to company-level performance targets, specifically net profit growth and anti-smoking drug sales revenue, alongside individual performance assessments. Failure to meet these targets results in the repurchase and cancellation of the restricted shares by the company. This initiative aims to align the interests of the core team with long-term shareholder value.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Shanxi Qianyuan Pharmaceutical Group Co., Ltd.

2026 Restricted Stock Incentive Plan Implementation Assessment Management Measures

Shanxi Qianyuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") has formulated these measures to further establish and improve the company's long-term incentive mechanism, attract and retain outstanding talent, and fully mobilize the enthusiasm of the company's directors, senior management, and core personnel. By effectively aligning the interests of shareholders, the company, and the core team, the company aims to encourage a shared focus on long-term development and enhance market competitiveness and sustainable development capabilities. Under the premise of fully protecting shareholder interests and adhering to the principle of matching rewards with contributions, the company intends to implement the 2026 Restricted Stock Incentive Plan (hereinafter referred to as the "Incentive Plan").

To ensure the smooth implementation of this Incentive Plan, these measures have been formulated in accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Administrative Measures for Equity Incentives of Listed Companies, the Rules Governing the Listing of Stocks on the ChiNext Market of the Shenzhen Stock Exchange, and other relevant laws, regulations, and normative documents, as well as the Articles of Association of Shanxi Qianyuan Pharmaceutical Group Co., Ltd.

I. Purpose of Assessment

The purpose is to further establish and improve the company's long-term incentive mechanism, attract and retain outstanding talent, and fully mobilize the enthusiasm of the company's directors, senior management, and core personnel. This effectively aligns the interests of shareholders, the company, and the core team, ensuring the smooth implementation of the 2026 Restricted Stock Incentive Plan and maximizing the effectiveness of equity incentives to achieve the company's development strategy and business goals.

II. Assessment Principles

The assessment must adhere to the principles of fairness, openness, and impartiality. Evaluations will be conducted strictly in accordance with these measures and the performance of the assessment targets, ensuring that the Incentive Plan is closely linked to the work performance and contributions of the incentive recipients, thereby improving overall company performance and maximizing the interests of the company and all shareholders.

III. Scope of Assessment

These measures apply to all incentive recipients participating in the company's Incentive Plan.

IV. Assessment Institutions

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.